Company

Sarepta Therapeutics

Sarepta Therapeutics has 25 drugs tracked on RxWires: 2 post-market, 5 in Phase 3, 4 in Phase 2, 6 in Phase 1/2, 8 in Phase 1.

Pipeline

Drug	Phase	Indication
ELEVIDYS	Post-Market	Duchenne Muscular Dystrophy
Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]	Post-Market	Duchenne Muscular Dystrophy
delandistrogene moxeparvovec	Phase 3	Duchenne Muscular Dystrophy
eteplirsen	Phase 3	Duchenne Muscular Dystrophy (DMD)
SRP-9005	Phase 3	Muscular Dystrophies, Limb-Girdle
SRP-4045	Phase 3	Duchenne Muscular Dystrophy
SRP-9003	Phase 3	Limb-girdle Muscular Dystrophy
RESTEN-MP	Phase 2	Coronary Artery Disease
AVI-5126	Phase 2	Cardiovascular Disease
AVI-4658 (Eteplirsen)	Phase 2	Duchenne Muscular Dystrophy (DMD)
Amondys 45	Phase 2	Duchenne Muscular Dystrophy
SRP-5051	Phase 1/2	Muscular Dystrophy, Duchenne
SRP-1003 IV Infusion	Phase 1/2	Myotonic Dystrophy 1
SRP-1001 for Injection	Phase 1/2	Muscular Dystrophy, Facioscapulohumeral
AVI-4658 for Injection	Phase 1/2	Duchenne Muscular Dystrophy
SRP-9004	Phase 1/2	Limb-Girdle Muscular Dystrophy, Type 2D
AVI-4065 Injection	Phase 1/2	Hepatitis C
AVI-6003	Phase 1	Marburg Hemorrhagic Fever
AVI-7537	Phase 1	Ebola Hemorrhagic Fever
SRP-6004	Phase 1	Limb Girdle Muscular Dystrophy
AVI-4020 Injection	Phase 1	West Nile Virus
AVI-6002	Phase 1	Ebola Hemorrhagic Fever
AVI-7288	Phase 1	Marburg Hemorrhagic Fever
rAAVrh74.MHCK7.DYSF.DV	Phase 1	Dysferlinopathy
SRP-1005	Phase 1	Huntington's Disease

Follow Sarepta Therapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.

Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.